3 completed, 1 terminated. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Ciraparantag: new trials by email Literature Review of Ciraparantag trials Research Report on Ciraparantag
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device) - Healthy | Phase 2 | Terminated | AMAG Pharmaceuticals, Inc. | 41 | 2021-10-13 | 2026-04-20 |
| Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT Ciraparantag, Placebo, Apixaban - Healthy | Phase 2 | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | 60 | 2017-08-30 | 2025-09-02 |
| Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT Ciraparantag, Placebo, Rivaroxaban - Healthy | Phase 2 | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | 69 | 2017-05-08 | 2025-09-02 |
| Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban PER977, Placebo - Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation | Phase 1 | Completed | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | 83 | 2013-07-01 | 2020-05-28 |
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. (3) · AMAG Pharmaceuticals, Inc. (1)
United States (4)